Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Liver Cirrhosis
Conditions
Liver Cirrhosis
Trial Timeline
Feb 15, 2024 → Dec 11, 2024
NCT ID
NCT06269484About Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozin
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozin is a phase 2 stage product being developed by AstraZeneca for Liver Cirrhosis. The current trial status is completed. This product is registered under clinical trial identifier NCT06269484. Target conditions include Liver Cirrhosis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06269484 | Phase 2 | Completed |
Competing Products
20 competing products in Liver Cirrhosis